Ketas (ibudilast) vs Relyvrio (sodium phenylbutyrate and taurursodiol)

Ketas (ibudilast) is a phosphodiesterase inhibitor that has been primarily used in Asia for the treatment of asthma and post-stroke complications, and it is currently being investigated for its potential off-label use in neurodegenerative disorders such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), due to its anti-inflammatory and neuroprotective properties. Relyvrio (sodium phenylbutyrate and taurursodiol), on the other hand, is a combination drug that has been FDA-approved specifically for the treatment of ALS; it is believed to work by reducing neuronal cell stress and improving mitochondrial function. When deciding between Ketas and Relyvrio, a patient with ALS should consider that Relyvrio is approved for this condition and has evidence supporting its use in this specific context, while Ketas's use for ALS would be off-label and its efficacy in this indication is less established.

Difference between Ketas and Relyvrio

Metric	Ketas (ibudilast)	Relyvrio (sodium phenylbutyrate and taurursodiol)
Generic name	Ibudilast	Sodium phenylbutyrate and taurursodiol
Indications	Asthma, stroke, and multiple sclerosis (off-label)	Amyotrophic lateral sclerosis (ALS)
Mechanism of action	Phosphodiesterase inhibitor, increases cyclic AMP and GMP	Neuroprotective and anti-inflammatory effects, improves mitochondrial function
Brand names	Ketas	Relyvrio
Administrative route	Oral	Oral
Side effects	Nausea, dizziness, headache	Nausea, diarrhea, abdominal pain
Contraindications	Known hypersensitivity to ibudilast or any component of the formulation	Known hypersensitivity to any component of the formulation
Drug class	Phosphodiesterase inhibitor	Combination of drugs with neuroprotective and mitochondrial function enhancement properties
Manufacturer	Kyorin Pharmaceutical Co., Ltd.	Amylyx Pharmaceuticals, Inc.

Efficacy

Efficacy of Ketas (Ibudilast) in ALS

The efficacy of Ketas, known generically as ibudilast, in the treatment of Amyotrophic Lateral Sclerosis (ALS) has been explored in clinical studies, although it is not currently approved for this indication. Ibudilast is a phosphodiesterase inhibitor that exhibits anti-inflammatory and neuroprotective properties. Its potential efficacy in ALS is hypothesized to be due to its ability to modulate the activity of microglia and to reduce the release of pro-inflammatory cytokines, which are believed to contribute to the progression of ALS. However, the results from clinical trials have been mixed, and more research is needed to fully understand the potential benefits of ibudilast in ALS patients.

Efficacy of Relyvrio (Sodium Phenylbutyrate and Taurursodiol) in ALS

Relyvrio, a combination of sodium phenylbutyrate and taurursodiol, has been approved by the FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS). This medication has shown efficacy in slowing the decline in physical function in people with ALS. The CENTAUR clinical trial, which was pivotal in the approval of Relyvrio, demonstrated that patients taking the drug experienced a slower rate of decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score compared to those on placebo. The ALSFRS-R is a validated rating instrument for monitoring the progression of disability in ALS patients.

The mechanism of action of Relyvrio is believed to be multifaceted, targeting cellular pathways that are implicated in the pathogenesis of ALS. Sodium phenylbutyrate is thought to help reduce neuronal stress, while taurursodiol may improve mitochondrial function. The combination of these two compounds is thought to confer a synergistic effect that may protect motor neurons from the degenerative processes characteristic of ALS.

It is important to note that while Relyvrio has shown efficacy in clinical trials, its effects can vary among individuals, and it is not a cure for ALS. The treatment aims to slow the progression of the disease and improve the quality of life for patients. As with any medication, the decision to use Relyvrio should be made in consultation with a healthcare provider, taking into account the potential benefits and risks for the individual patient.

Regulatory Agency Approvals

Ketas

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Relyvrio

Food and Drug Administration (FDA), USA

Access Ketas or Relyvrio today

If Ketas or Relyvrio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Ketas

Buy Relyvrio

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: